Payment overview · 2025
General Payments
$2,834.65
111 reported records · 24 companies
Healthcare provider profile · identity verified
Brittany Stuart, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · BROOKLYN, NY · NPI 1184366098
Verified facts
What the public records show
CMS Open Payments records show Brittany Stuart, PA received $2,834.65 in general payments during 2025 across 111 reported records.
Alexion Pharmaceuticals, Inc. accounted for 14.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Amvuttra, Austedo Xr, Nuplazid.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Nuplazid by this doctor in 2024.
Alnylam Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AMVUTTRA as an associated drug or biological on 15085 records involving 6358 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Amvuttra by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ONGENTYS as an associated drug or biological on 728 records involving 311 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ongentys by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Rytary by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PANZYGA as an associated drug or biological on 8346 records involving 3334 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Panzyga by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $412.86 | 14.6% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $281.07 | 9.9% | 5 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $211.75 | 7.5% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $191.35 | 6.8% | 5 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $190.08 | 6.7% | 9 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$184.52 | 6.5% | 10 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $151.76 | 5.3% | 8 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $148.47 | 5.2% | 14 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $135.14 | 4.8% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $131.40 | 4.6% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $115.85 | 4.1% | 4 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $106.81 | 3.8% | 5 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $106.05 | 3.7% | 4 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $84.38 | 3.0% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $76.92 | 2.7% | 3 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $74.08 | 2.6% | 2 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $60.24 | 2.1% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $30.71 | 1.1% | 2 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $27.16 | 1.0% | 1 | 2025 |
| Life Molecular Imaging Ltd | Unresolved — no canonical attribution shown | $25.36 | 0.9% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.58 | 0.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $22.52 | 0.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.32 | 0.8% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $20.27 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,711.63 | 107 |
| Travel and Lodging | $100.99 | 2 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $22.03 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $288.49 | 9 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $281.07 | 5 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $211.75 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $158.15 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $158.15 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $151.76 | 8 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $149.48 | 7 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $146.65 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $135.14 | 6 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $115.85 | 4 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $114.08 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $106.81 | 5 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $84.38 | 3 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $76.92 | 3 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $62.30 | 6 | 2025 |
Source payment records
|
|||||
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $49.67 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $42.38 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $33.20 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $30.71 | 2 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $27.16 | 1 | 2025 |
Source payment records
|
|||||
| NEURACEQ Normalized: neuraceq |
Drug | Life Molecular Imaging Ltd | $25.36 | 1 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $24.58 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.32 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $21.32 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $17.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AMVUTTRA amvuttra |
2025 | Amvuttra | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Alnylam Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | AMVUTTRA open payments reported associated product |
CMS Open Payments — General Payments 15085 supporting records · 6358 recipient NPIs · example record 1212737037 |
Amvuttra · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | ONGENTYS open payments reported associated product |
CMS Open Payments — General Payments 728 supporting records · 311 recipient NPIs · example record 1220525547 |
Ongentys · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
47 | 15 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PANZYGA open payments reported associated product |
CMS Open Payments — General Payments 8346 supporting records · 3334 recipient NPIs · example record 1228795271 |
Panzyga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 211 | 94 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 146 | 63 |
| Gabapentin | Gabapentin | 112 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 45 |
| Memantine Hcl | Memantine Hcl | 96 | 42 |
| Pregabalin | Pregabalin | 88 | 33 |
| Nortriptyline Hcl | Nortriptyline Hcl | 81 | 45 |
| Quetiapine Fumarate | Quetiapine Fumarate | 80 | 39 |
| Memantine Hcl Er | Memantine Hcl | 74 | 29 |
| Doxepin Hcl | Doxepin Hcl | 70 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | 15 |
| Oxcarbazepine | Oxcarbazepine | 47 | 16 |
| Rytary | Carbidopa/Levodopa | 47 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 25 |
| Rivastigmine | Rivastigmine | 46 | 16 |
| Levetiracetam | Levetiracetam | 43 | 15 |
| Ropinirole Er | Ropinirole Hcl | 41 | 17 |
| Nuplazid | Pimavanserin Tartrate | 36 | suppressed |
| Neupro | Rotigotine | 35 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 33 | 14 |
| Atorvastatin Calcium | Atorvastatin Calcium | 30 | 18 |
| Mirtazapine | Mirtazapine | 28 | 12 |
| Rivastigmine | Rivastigmine Tartrate | 28 | 12 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 27 | 12 |
| Topiramate | Topiramate | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 24 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 20 | suppressed |
| Amantadine | Amantadine Hcl | 19 | suppressed |
| Baclofen | Baclofen | 19 | 11 |
| Clonazepam | Clonazepam | 19 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 19 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 18 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 16 | suppressed |
| Amvuttra | Vutrisiran Sodium | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 16 | suppressed |
| Panzyga | Immun Glob G(Igg)-Ifas/Glycine | 16 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 16 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Zonisamide | Zonisamide | 15 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 14 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 13 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Austedo Xr | Deutetrabenazine | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Entacapone | Entacapone | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Ongentys | Opicapone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,834.65 · 111 records | Alexion Pharmaceuticals, Inc. | AMVUTTRA, AUSTEDO XR, BOTOX, CREXONT, Dysport, ELIQUIS, GOMEKLI, Gamunex-C, Gocovri, INBRIJA, INFINITY, KEVEYIS, KRYSTEXXA, LEQEMBI, Mavenclad, NEURACEQ, NUPLAZID, PAXLOVID, QULIPTA, REXULTI, UBRELVY, ULTOMIRIS, UPLIZNA, VUMERITY, VYEPTI, VYVGART HYTRULO, Xeomin | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Amvuttra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ACADIA Pharmaceuticals Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error